DAYBUE STIX - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Lexeo’s second cardiac gene therapy gains FDA support ahead of year-end update

Early lung cancer responses push ACR-2316 into a broader randomized trial

Arctic oilfield and pipeline construction in Alaska, illustrating how ConocoPhillips’ Willow Project is advancing toward early-2029 first oil after being reported 50% complete following its winter build. Representative image.

Willow Project: ConocoPhillips’ Alaska oil development advances toward early-2029 first production

A fresh missile attack on an ADNOC-linked vessel has intensified Strait of Hormuz security concerns just as Iran and Oman move closer to a new shipping arrangement for the vital global energy route. Representative image.

UAE says Iranian missile hit ADNOC-linked vessel as Strait of Hormuz deal hangs in balance

Read More

Pharma Industry News

Neuren Pharmaceuticals (ASX: NEU) lifts 2026 royalty outlook after record DAYBUE quarter

Record DAYBUE sales and rapid adoption of its STIX formulation have strengthened Neuren Pharmaceuticals’ royalty outlook, while Europe and Japan offer the next major tests of the franchise’s global potential.

August 5, 2026

web analytics